Elevated levels of tumor necrosis factor alpha (TNF-a) have been reported to correlate with the development of transplant-related complications after bone marrow transplantation (BMT). In a recent phase 1-11 trial, oral administration of pentoxifylline (PTX), a xanthine derivative capable of downregulating TNF-(U production in vitro, was reported to reduce morbidity and mortality in patients undergoing BMT. We conducted a prospective randomized trial of PTX therapy among 140 patients undergoing either allogeneic (n = 51) or autologous BMT (n = 89). Patients were randomized to receive (n = 70) or not receive (n = 70) oral PTX, 1,600 mg/d in four divided doses from day -8 until day + 100 post-BMT. The incidence of mucositis requiring morphine sulfate (MS04) was similar in both groups (42.9%), with the mean number of days with MS04 being 7.8 (SD = 3.4) in the PTX group versus 8.2 (SD = 3.4) in the control group (NS). The incidence of renal insufficiency OXICITIES CAUSED BY chemotherapy and radio-T therapy used to prepare patients for bone marrow transplantation (BMT) remain a major cause ofpatient morbidity and mortality after allogeneic or autologous BMT. Indeed, transplant-related mortality associated with allogeneic BMT is still about 30% and vanes from 10% to 20% after autologous BMT.' Recently, the development of various transplant-related complications, including hepatic veno-occlusive disease (VOD), interstitial pneumonitis (IP), endothelial leakage syndrome (ELS), infections and acute graft-versus-host disease (GVHD), has been related with elevated plasma levels of tumor necrosis factor alpha (TNFa), which suggests a role for this inflammatory mediator in the initiation or amplification of tissue injury after BMT?
T therapy used to prepare patients for bone marrow transplantation (BMT) remain a major cause ofpatient morbidity and mortality after allogeneic or autologous BMT. Indeed, transplant-related mortality associated with allogeneic BMT is still about 30% and vanes from 10% to 20% after autologous BMT.' Recently, the development of various transplant-related complications, including hepatic veno-occlusive disease (VOD), interstitial pneumonitis (IP), endothelial leakage syndrome (ELS), infections and acute graft-versus-host disease (GVHD), has been related with elevated plasma levels of tumor necrosis factor alpha (TNFa), which suggests a role for this inflammatory mediator in the initiation or amplification of tissue injury after BMT?
Pentoxifylline (PTX) is a xanthine derivative that has been shown to downregulate TNF-a production by monocytes/macrophages in vitro,5 to decrease radiation-induced TNF-a production in experimental models,6 and to decrease endotoxin-induced TNF-a production in healthy volunteers.' Furthermore, PTX was reported to stimulate vascular endothelial production of prostaglandins (PGs) I, and E2 enhancing locoregional blood flow in the liver and the kidney and promoting thromb~lysis.*-~ Because endothelial production of PGs I2 and E, has been reported to be depressed following irradiation," it was reasonable to specu- [46%] in the control group). No significant difference was observed in hematologic toxicity, transfusion requirements, duration of fever, and hepatic toxicity between the treatment groups. In conclusion, our study failed to show a prophylactic effect of PTX in transplant-related toxicities after BMT. On the basis of these findings, we cannot recommend that PTX be part of early mortality and morbidity prevention programs after BMT. 0 1993 by The American Society of Hematology.
late that PTX administration could decrease BMT-related toxicities via the inhibition of TNF-a production and/or the stimulation of endothelial production of PGs I,/E2. Recently, Bianco et al reported that oral administration of PTX in doses up to 2,000 mg/d was well tolerated and associated with a reduction in morbidity and mortality after allogeneic or autologous BMT compared with historical control patients." The impact of such a prophylactic effect of PTX could be considerable in the BMT setting because PTX would decrease regimen-related toxicities, permit the delivery of higher doses of chemoradiotherapy resulting in a lower relapse rate, and ultimately improve event-free survival after BMT." Therefore, a controlled trial was warranted to test the efficacy of PTX in preventing BMT-related toxicities. We report the first trial designed to address this crucial issue. One hundred forty patients were randomized to receive or not receive PTX after either autologous or allogeneic BMT.
MATERIALS AND METHODS
Requirements for patient enrollment. All patients admitted to the BMT unit of Purpan Hospital from December 1990 to September 1992, who were to receive unpurged autologous or non-Tdepleted HLA genoidentical allogeneic BMT, prepared with standard regimens, were eligible for this study. Standard regimens included ( I ) cyclophosphamide (CY) (120 mg/kg) and total body irradiation (TBI) (12 Gy); (2) CY (120 mg/kg) and busulfan (BU) (16 mg/kg); (3) melphalan (MEL) (140 mg/m2) and TBI (8 Cy); (4) CY (6 g/m2), etoposide (1 g/m2), and carmustine (300 mg/m2) (CBV). According to the criteria stated above, 10 patients were excluded for the following reasons: 7 patients had received nonstandard preparative regimens, and 3 patients had received a matched, unrelated allogeneic BMT. Informed consent was obtained either from patients or from one oftheir parents in accordance with institutional policy.
One hundred forty consecutive eligible patients were enrolled in the study. Their clinical characteristics are detailed in Table I None of the characteristics differed significantly between treatment groups.
tients were treated for the following diseases: 26 for acute myelogenous leukemia (AML), 29 for acute lymphoblastic leukemia (ALL), 17 for chronic myelogenous leukemia (CML), 33 for malignant lymphoma, and 29 for multiple myeloma. Twelve patients (8.5%) had an abnormal aspartate aminotransferase value (SGOT) before BMT (laboratory norms, 1 4 0 IU). Seven patients (5%) had abnormal total serum bilirubin before BMT (laboratory norms, <19 pmol/L). None of the patients had positive serology for hepatitis B antigen before BMT. Fifty patients (35.7%) had positive serology for cytomegalovirus (CMV) before BMT. Ten days before transplantation, patients were randomized to receive or not receive PTX. The treatment allocation for each patient was assigned via telephone by the biostatistics department, which had prepared before initiation ofthe trial a computer-generated sequence unknown to the physicians participating in the trial. Randomization was stratified according to the type of graft (allogeneic/autologous). Prophylactic PTX, 1,600 mg, was administered orally in four divided daily doses, starting on the day preparative therapy began until 100 days posttransplant. Pills were crushed and mixed with liquid for patients who experienced difficulty swallowing intact caplets. Vomited doses were repeated if vomiting occured within 30 minutes of administration. Omitted pills, if any, were recorded from day -8 until day f45.
Preparative regimens are detailed in Table 1 . Eighty-seven patients (62.2%) received a TBI-containing regimen, 25 patients received a BU-CY regimen (17.8%), and 28 patients Study design.
EMTprocedures.
received the CBV regimen (20%). Patients received autologous unpurged cryopreserved graft or non-T-depleted allogeneic graft on day 0. Prevention of GVHD was attempted by the administration of methotrexate (1 5 mg on days + 1, +3, and +6) plus cyclosporine.
Patients were treated in laminar air flow or positive-pressure rooms with usual aseptic precautions. All patients received sterile diet. A total gut decontamination regimen with oral nonabsorbable antibiotics (cephalosporine, gentamicin, bacitracin) was started on day 8 before BMT. Patients received fluconazole for prophylaxis of fungal infections, acyclovir for prevention of herpes infections, and ranitidine for prophylaxis of upper gastrointestinal tract bleeding. Prophylaxis of VOD was attempted by the continuous infusion of low-dose heparin (100 U/kg/d) from day -8 until day +30 post-BMT in 120 patients (85.7%)." Blood products were irradiated before transfusion. Neither prophylactic nor therapeutic granulocyte transfusion was used. No prophylactic hematopoietic growth factor was used after BMT. A central venous catheter was inserted surgically 1 week before admission to the sterile unit.
Renal insufficiency was defined as a twofold or more increase in baseline serum creatinine. The diagnosis of hepatic VOD required the presence of hyperbilirubinemia (234 pmol/L), weight gain 2 5 % ofbaseline weight, and right upper quadrant pain with hepatomegaly." Severity of mucositis was scored in accordance with previously published criteria,14 and the number of days of continuous morphine sulfate (MS04) administration was used to compare treatment groups. A patient was defined to be refractory to platelet transfusions if the platelet count remained below the pretransfusion level 24 hours after platelet transfusions during 5 consecutive days.
Statistical analysis. The proportions of patients with a given characteristic were compared by x2 test or Fischer's exact test. Differences in the means of continuous measurements were tested with Student's t test, controlled by nonparametric Mann-Whitney U test. All tests were two-sided. PTX has been reported dramatically to decrease four major regimen-related toxicities, including severe mucositis (requiring MS04), renal insufficiency (twofold or more increase in baseline serum creatinine), severe GVHD, and V0D.I' We previously reported that the heparin regimen we used was associated with a low rate of VOD.I2 Thus, hepatic dysfunction was not considered as an endpoint in this study. At our institution, the rates of severe mucositis, renal insufficiency, and grades 3 to 4 GVHD are 4570, 25%, and 23%, respectively. According to Bianco et al,"
the rates of severe mucositis, renal insufficiency, and grades 3 to 4 GVHD were expected to decrease to 20%, 7%, and 1%, respectively, in the PTX group. To ensure a significance level of 5% and a power of 10% to these assumptions, a minimum of 70 patients (including 25 patients undergoing allogeneic BMT) assigned randomly to each treatment arm was required. The study was completed by an enrollment of 140 patients.
Toxicity definitions.
RESULTS

Randomization.
Seventy patients were randomly assigned to each treatment group. As shown in Table I , patient characteristics of each group were similar, and no significant differences were found with regard to age, sex, underlying disease, type of graft, preparative regimen, pre-BMT serology of hepatitis B and cytomegalovirus (CMV), and pre-BMT value of SGOT, bilirubin, and creatinine.
No patient experienced adverse side effects related to PTX administration. The compliance was satisfactory. Indeed, all patients received oral PTX with >95% of prescribed doses. During early neutropenia, four patients did not receive the full course of PTX
PTX tolerance and compliance.
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Hematologic toxicity and transfusion requirements. As shown in Table 2 , the mean duration of neutropenia (<500/ mm3), the mean duration of thrombocytopenia (<25,000/ mm'), and the mean number of platelet and RBC transfusions were not affected by PTX administration.
Infections during the first 100 days post-BMT. As shown in Table 2 , the mean duration of fever above 38°C during neutropenia was not significantly different between the two groups. Septicemia (two or more positive blood cultures) occured in 13/70 patients in the PTX group versus 9/70 patients in the control group (NS). One patient died of septicemia (Pseudomonas) in the control group. Among allogeneic patients, the incidence of CMV viremia and interstitial pneumonitis were similar in both groups: 7/25 and 2/25, respectively, in the PTX group versus 9/26 and 4/26, respectively, in the control group (NS).
Organ toxicities during thefirst 100 days post BMT. As shown in Table 3 , no significant differences were found with regard to renal toxicity between the treatment groups. The highest creatinine value and the number of patients with renal insufficiency were similar in both groups. Among allogeneic patients, PTX did not affect the number of patients requiring an interruption of cyclosporine for renal toxicity (creatinine >160 pmol/L): 5/25 in the PTX group versus 6/26 in the control group (NS). The incidence and severity of mucositis were not decreased by PTX administration. Indeed, 30170 (42.9%) patients in each group required MS04 for grade I1 or higher mucositis. The mean duration of continuous MS04 administration was similar in both groups: 7.8 days(SD = 3.4) in the PTX group versus 8.2 days (SD = 3.4) in the control group No significant differences were found with regard to hepatic toxicities between the treatment groups. The highest value of bilirubinemia and the incidence of VOD were similar in two groups: 26.4 pmol/L (SD = 31.7) and 3/70 patients, respectively, in the PTX group versus 24.4 pmol/L (W. 
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(SD = 46.1) and 2/71 patients, respectively, in the control group (NS). The mean duration of hospital admission was similar in both groups: 3 1.2 days (SD = 6.4) in the PTX group versus 32 days (SD = 7.5) in the control group (NS).
As shown in Table 3 , the incidence and severity of acute GVHD were not statistically different between treatment groups.
Within the first 100 days post-transplant, 6/70 patients died in the PTX group (early relapse, one case; GVHD, two cases; VOD, two cases; CMV pneumonitis, one case) versus 6 of 70 in the control group (GVHD, three cases; septicemia, one case; VOD, one case; CMV pneumonitis, one case).
Acute GVHD.
Day 100 survival.
DISCUSSION
BMT-related mortality has decreased significantly during the last few years.' However, the early mortality associated with allogeneic BMT is still about 30% even in "good-risk" patients and varies from 10% to 20% after autologous BMT. Life-threatening toxicities after BMT result not only from infections, bleeding, and GVHD but also from direct organ toxicities of the conditioning regimens, including VOD, ELS, IP, and mucosal toxicities. Recently, several reports have suggested a pathogenetic role of TNF-a in infections,15 in GVHD, and also in regimen-related toxicities such as VOD, ELS, and IP.2-4 Thus, the prophylactic use of agents able to decrease monocyte/macrophage production of TNF-a seemed to be a logical approach to prevent BMT-related toxicities. Recently, Bianco et al, in a phase 1/11 study, administered PTX in 30 patients undergoing allogeneic/autologous BMT. 'I These investigators reported a highly signifFor personal use only. on September 14, 2017. by guest www.bloodjournal.org From icant decrease in BMT-related toxicities, including renal insufficiency, hepatic dysfunction, mucositis, and GVHD, compared with 20 historical control patients. In a subsequent study, Bianco et a1 reported that PTX administration to patients with lymphoma undergoing autologous/allogeneic BMT prepared with CBV, was associated with a reduction of day 100 nonrelapse mortality compared with historical control patients. 16 The interest of such an effective and inexpensive prophylaxis of BMT-related toxicities would be considerable. However, the apparent beneficial effects of PTX have only been observed when compared with historical control groups of patients. Thus, prospective randomized studies are required to confirm these observations.
In our prospective study, 140 patients undergoing BMT were randomized to receive or not receive oral PTX, 1,600 mg, in four divided daily doses from day -8 until day + 100.
Because of concern about oral administration of placebo pills in informed patients with severe mucositis, our study was not placebo controlled. Therefore, only objectively evaluable endpoints were selected to compare treatment groups. Oral administration of PTX was chosen according to Bianco et al.' ' They demonstrated that all patients tolerated oral PTX with >95% of prescribed dose. Furthermore, they reported that bioavailability of the oral formulation in transplant patients receiving cyclosporine and methotrexate for GVHD prophylaxis was similar to that seen in healthy volunteers. A PTX dosage of 1,600 mg in four divided daily doses was chosen in our trial. Indeed, Bianco et al demonstrated that there were no significant differences in assayable plasma levels of TNF between recipients of 1,600 or 2,000 mg/d." Furthermore, they reported that "there did not appear to be additional benefits from the increased dose when compared with 1,600 mg/d."" Therefore, because of concerns about patient compliance, the dose of 1,600 mg in four divided daily doses rather than 2,000 mg in five divided daily doses was chosen for this trial.
The main objectives of our trial were to evaluate the impact of PTX administration on the incidence of renal insufficiency, severe mucositis, and severe GVHD (see statistical analysis). Our trial failed to observe a prophylactic effect of PTX. Indeed, the incidence of severe mucositis, renal insufficiency, and grade 2 or higher GVHD were 42.9%, 2 1.4%, and 46.1%, respectively, in the control group versus 42.9%, 15.7%, and 44%, respectively, in the PTX group (NS). These results were confirmed when highest value of serum creatinine, mean number of days with MS04 for severe mucositis, and grades 3 to 4 GVHD were compared between the two groups (103.9 pmol/L [SD = 571, 8.2 days [SD = 3.41, and 23.1%, respectively, in the control group, versus 1 I9 pmol/L (SD = 82.4), 7.8 days (SD = 3.4), and 20%, respectively, in the PTX group [NS]). Furthermore, no significant difference was observed between two groups with regard to duration of fever, hematologic toxicity, transfusion requirements, and day 100 survival. The incidence of VOD was not considered as an endpoint in our study. Indeed, we previously reported that the heparin regimen we used was associated with a low rate of VOD." The present study confirmed our previous findings; namely, only 5/ 140 patients (3.5%) developed VOD after BMT (2 patients in the control group v 3 patients in the PTX group).
Recently, Kalhs et al reported that continuous infusion of PTX (12 to 30 mg/kg/d) did not decrease regimen-related toxicities in 3 I consecutive allogeneic recipient^.'^ However, in the latter study, the administration schedule may have hampered the efficacy of PTX. Indeed, Bianco et a1 have reported that peak plasma (Cmax) and area under curve (AUC) concentration of PTX were lower in patients treated with continuous infusion than in patients treated with oral form~1ation.l~ Thus, difference in drug delivery resulting in differences in Cmax and AUC could have played a role in the differences in outcome observed between the studies of Bianco et a1 and Kahl et al." In our study, although PTX was administered orally as recommended by Bianco et al," we failed to observe a prophylactic effect of PTX. The reasons for the discrepancy between our results and these of Bianco et a1 remain unclear. However, several factors distinguish the two studies. Most of the patients in the study of Bianco et a1 were considered "high risk," either because of age, advanced disease, preparative regimen, or donor status, and were compared with a historical "good-risk" group. In our prospective randomized study, patients received conventional chemotherapy regimens, were enrolled at an initial phase of their primary disease, and received autologous or HLA genoidentical allogeneic grafts.
In conclusion, oral administration of PTX was found to be ineffective in the prophylaxis of BMT-related toxicities. On the basis of these findings, we cannot recommend the administration of PTX after BMT. Recently, combined therapy with pharmacologic agents (PTX, ciprofloxacin, prednisone) that inhibit TNF synthesis at different points in the synthetic pathway was reported to reduce regimen-related toxicity and to accelerate engraftment after BMT. The role of such combined therapy could be evaluated in further prospective trials.
